Background: Tinea corporis is a common dermatophytic infection in Bangladesh. Increasing chronicity, treatment failure, recurrence, and reduced responsiveness to conventional antifungal regimens have created important therapeutic challenges. Objective: To compare clinical cure and relapse rates associated with three itraconazole regimens used for tinea corporis in routine dermatological practice. Methods: This prospective, real-world observational study was conducted in private dermatology practices in Dhaka and Mymensingh, Bangladesh. Patients aged 15–50 years with clinically diagnosed tinea corporis were enrolled consecutively when they met the predefined eligibility criteria. Seventy-two patients were initially enrolled; 12 were excluded because of adverse effects, clinically relevant drug interactions, non-adherence, or loss to follow-up. The final per-protocol analysis included 60 patients, with 20 in each non-randomized treatment group. Group A received itraconazole capsules 200 mg twice daily for 2 weeks followed by 100 mg twice daily for 6 weeks; Group B received itraconazole capsules 100 mg twice daily for 8 weeks; and Group C received itraconazole tablets 200 mg once daily for 8 weeks. All groups also received topical luliconazole once daily, a 6% salicylic acid preparation at night, and daily ciclopirox shampoo wash. Clinical cure was assessed at treatment completion, and cured patients were followed for 6 months to assess relapse. Results: Clinical cure was achieved in 19/20 patients in Group A (95%; 95% confidence interval [CI], 76.4%–99.1%), 16/20 in Group B (80%; 95% CI, 58.4%–91.9%), and 9/20 in Group C (45%; 95% CI, 25.8%–65.8%) (?²=13.47; p=0.001). Relapse occurred in 2/19 cured patients in Group A (10.5%; 95% CI, 2.9%–31.4%), 5/16 in Group B (31.3%; 95% CI, 14.2%–55.6%), and 7/9 in Group C (77.8%; 95% CI, 45.3%–93.7%) (?²=12.74; p=0.002). Among the 72 enrolled patients, exclusions included leg oedema in 6, clinically relevant drug interactions in 3, headache in 2, and suspected cardiac toxicity in 1. Conclusion: The Group A regimen was associated with the most favourable clinical outcome, whereas the once-daily tablet regimen showed comparatively lower effectiveness in this cohort. However, the non-randomized design, small sample, per-protocol analysis, potential confounding, adjunctive therapy, and absence of mycological confirmation preclude definitive conclusions regarding comparative superiority. Larger prospective randomized studies incorporating standardized clinical assessment and mycological evaluation are required